The FDA on March 29 approved Mavenclad tablets to treat relapsing forms of multiple sclerosis in adults, to include relapsing-remitting disease and active secondary progressive disease.
- The FDA granted approval of Mavenclad to EMD Serono, it said in a statement
©2019 Bloomberg L.P. All rights reserved. Used with permission
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.